<DOC>
	<DOCNO>NCT00371995</DOCNO>
	<brief_summary>Miltefosine liposomal amphotericin B ( AmBisome ) approve drug visceral leishmaniasis . In study drug give sequential manner . AmBisome give day 1 , follow Miltefosine 14 day . Final Cure evaluate six month .</brief_summary>
	<brief_title>Short Course Miltefosine Liposomal Amphotericin B Kala-azar</brief_title>
	<detailed_description>Methodology Multicenter trial , eligible patient treat Liposomal amphotericin B ( 5 mg/kg ) day 1 miltefosine capsule 14 day ( day 2-15 ) . At two week end treatment initial cure ( clinical parasitological cure ) clinical response determine . If initial cure observe , patient evaluate 6 month ( end treatment ) follow period final clinical cure . Number patient plan Total number patient plan : 150 patient center combine . 75 pediatric ( 2-11 year ) ; 75 adult ( 12-65 year ) . Lack suitability trial : - Post Kala-azar Dermal Leishmaniasis ( PKDL ) - Concomitant treatment anti-leishmanial drug - Any condition compromise ability comply study procedure Administrative reason : - Any condition situation compromise compliance study procedure include follow-up visit Study medication , dose mode administration Liposomal amphotericin B administer intravenously single dose day 1 , Dosage : 5 mg/kg . Miltefosine administer orally ( 50 mg capsule ) 14 day ( day 2-15 ) Dosage : 1. weigh â‰¥ 25 kg : 100 mg miltefosine daily one capsule ( 50 mg ) morning one capsule evening , meal 14 day . 2. weigh &lt; 25 kg : 50 mg miltefosine daily one capsule ( 50 mg ) morning , meal 14 day . Parameter evaluation - Final cure rate ( initial parasite cure clinical assessment six month EOT ) - Initial parasitological cure rate ( base splenic aspirate Bone marrow aspirate ) - Clinical response end treatment ( clinical assessment ) - Adverse event Statistical method - Calculation cure rate 95 % 90 % low confidence limit accord Clopper Pearson - Calculation overall incidence adverse event</detailed_description>
	<mesh_term>Leishmaniasis</mesh_term>
	<mesh_term>Leishmaniasis , Visceral</mesh_term>
	<mesh_term>Amphotericin B</mesh_term>
	<mesh_term>Liposomal amphotericin B</mesh_term>
	<mesh_term>Miltefosine</mesh_term>
	<criteria>Male female age 2 65 year ( inclusive ) Parasites visualized splenic aspiration Signs symptom compatible visceral leishmaniasis ( e.g . fever , splenomegaly , anaemia , weight loss , leucopenia , thrombocytopenia ) Confirmed diagnosis VL visualization parasites splenic/bone marrow aspirate Fever least 2 week Written inform consent patient/or parent guardian 18 year old Hemoglobin &lt; 6 g/dl White blood cell count &lt; 1000/mm3 Platelets &lt; 50,000 Prothrombin time &gt; 5 sec control ASAT &gt; 3 time upper limit normal Serum creatinine BUN &gt; 1.5 time upper limit normal Malaria Tuberculosis HIV positive serology Lactation , pregnancy Refusing contraception method treatment period plus 3 month Any medical condition ( ) upon judgment physician may affect safety patient treat study drug Any concomitant drug nephrotoxic</criteria>
	<gender>All</gender>
	<minimum_age>2 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>September 2008</verification_date>
	<keyword>Visceral leishmaniasis</keyword>
	<keyword>kala-azar</keyword>
	<keyword>miltefosine</keyword>
	<keyword>AmBisome</keyword>
</DOC>